HBM Holdings (HKG:2142) investigational new drug application for HBM7575, a long-acting bispecific antibody for asthma treatment, has been approved by China's National Medical Products Administration.
HBM7575/SKB575, co-developed with Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990), targets thymic stromal lymphopoietin and an undisclosed target to treat asthma, according to a Wednesday Hong Kong bourse filing.
Shares of the company rose over 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments